The company’s Scotland-based facility has successfully completed a scheduled inspection by the UK’s MHRA; there were no critical or major observations noted.
Symbiosis Pharmaceutical Services, a CMO in parenteral manufacturing, announced that its Scotland-based facility has successfully completed a scheduled inspection by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). There were no critical or major observations noted.
Symbiosis has been re-inspected and approved for the ongoing production of investigational medicinal products for clinical trials. The company has received confirmation of continued authorization for the GMP manufacture of aseptically-filled licensed commercial products following initial approval of the commercial manufacturer’s/importers license in 2014.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Inspiration Over Desperation: Accurant Biotech CEO Talks Leadership, Innovation, and Motivation
March 4th 2025Xiao-Yan Cai, PhD, shares insights into her leadership style, the importance of motivation in the workplace, and how she balances repetition with innovation, discussing how hobbies and resilience uniquely shape her professional approach, emphasizing the value of perseverance and preparation in both science and life.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.